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BACKGROUND: Uterine leiomyomas (ULs) are the most common gynecologic tumors and affect 3 of every 4 women by the age of 
50 years. The majority of ULs are classified as conventional tumors, whereas 10% represent various histopathological subtypes with 
features that mimic malignancy. These subtypes include cellular and mitotically active ULs and ULs with bizarre nuclei. Uterine leio-
myosarcoma (ULMS), the malignant counterpart of UL, is an aggressive cancer with poor overall survival. The early diagnosis and 
preoperative differentiation of ULMS from UL are often challenging because their symptoms and morphology resemble one another. 
Recent studies have shown frequent loss of alpha-thalassemia/mental retardation syndrome X-linked (ATRX) or death domain–as-
sociated protein (DAXX) expression in ULMS, and this is often associated with an alternative lengthening of telomeres (ALT) pheno-
type. METHODS: To investigate ATRX and DAXX expression and the presence of ALT in UL subtypes, immunohistochemical and 
telomere-specific fluorescence in situ hybridization analyses were performed. The study material consisted of 142 formalin-fixed, 
paraffin-embedded tissue samples representing various UL subtypes and 64 conventional ULs. RESULTS: A loss of ATRX or DAXX 
and/or ALT was detected in 6.3% of the histopathological UL subtype samples (9 of 142). Two patients whose ULs showed either 
ATRX loss or ALT were later diagnosed with a pulmonary smooth muscle tumor. Pulmonary tumors displayed molecular alterations 
found in the corresponding uterine tumors, which indicated metastasis to the lungs. All conventional ULs displayed normal ATRX, 
DAXX, and telomeres. CONCLUSIONS: These results highlight the differences between conventional and histopathologically atypi-
cal ULs and indicate that some UL subtype tumors may harbor long-term malignant potential. Cancer 2018;124:4650-4656. © 2018 
American Cancer Society.
KEYWORDS: alpha-thalassemia/mental retardation syndrome X-linked (ATRX), death domain–associated protein (DAXX), alternative 
lengthening of telomeres (ALT), benign metastasizing leiomyoma, uterine leiomyoma, uterine leiomyosarcoma.
INTRODUCTION
Uterine leiomyomas (ULs) are the most common gynecologic neoplasms and affect approximately 75% of women by the 
age of 50 years.1 Despite their benign nature, ULs can disturb the uterine function and cause several health complica-
tions such as abnormal bleeding, pelvic discomfort, and reproductive dysfunction. ULs are the leading cause of hyster-
ectomy and cause a massive economic burden for health care systems.1 High-throughput sequencing has revealed that 
approximately 70% of conventional ULs harbor mutations in mediator complex subunit 12 (MED12).2 Other recurrent 
alterations include high-mobility group AT-hook 2 (HMGA2) overexpression (10%-20%) and fumarate hydratase (FH) 
inactivation (1%-2%), and together, these 3 driver aberrations account for 80% to 90% of the tumors.3
In addition to conventional ULs, there are several histopathological UL subtypes (herein called variants), such 
as cellular and mitotically active tumors and ULs with bizarre nuclei.4 These variant tumors are also considered clin-
ically benign and are treated accordingly, although some of their histopathological traits mimic malignancy. MED12, 
HMGA2, and FH alterations can be found in UL variants, but their combined contribution is considerably lower than 
that in conventional ULs.5,6
Uterine leiomyosarcoma (ULMS) is considered a malignant counterpart of UL. It is a rare but highly aggressive 
cancer with poor 5-year survival.7 The early diagnosis and preoperative differentiation of ULMS from UL are often 
challenging because of highly overlapping symptoms, and this raises the clinical concern that some ULMSs are treated 
and operated on as benign ULs. Currently, a postoperative histopathological examination is the only reliable method 
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to distinguish ULMS from UL. Despite recent advances, 
the pathogenesis of ULMS remains poorly understood. 
Recently, we and others have shown that the expression of 
alpha-thalassemia/mental retardation syndrome X-linked 
(ATRX) is lost in 39% to 52% and the expression of 
death domain–associated protein (DAXX) is lost in 0% 
to 2% of ULMSs.8,9 A loss of ATRX/DAXX has been 
associated with the alternative lengthening of telomeres 
(ALT) phenotype, which uses homologous recombina-
tion for telomere length maintenance instead of activa-
tion of the telomerase enzyme.10 ALT is used especially 
by brain tumors and soft-tissue sarcomas,11 and it has also 
been observed in the majority of ULMSs.8,9
Frequent loss of ATRX/DAXX expression and ALT 
in ULMSs prompted us to study whether these aberra-
tions could be seen in variant or conventional ULs. The 
presence of such alterations could indicate that some ULs 
harbor malignant potential and represent ULMS precur-
sor lesions.
MATERIALS AND METHODS
Two hundred six formalin-fixed, paraffin-embedded 
tumor samples representing several histopathological UL 
variants (n = 142) and conventional ULs (n = 64) were 
derived from the Department of Pathology of Helsinki 
University Hospital (Helsinki, Finland). The histopa-
thology was reexamined via the corresponding hematox-
ylin-eosin–stained slides by a pathologist specialized in 
gynecologic pathology (R.C.B. or A.M.P.). The variant 
UL samples include 35 cellular ULs, 45 highly cellular 
ULs, 31 mitotically active ULs (including 15 tumors also 
displaying cellularity [n = 7] or high cellularity [n = 8]), and 
31 ULs with bizarre nuclei. In addition to uterine tumors, 
3 pulmonary smooth muscle tumor samples from patients 
who were earlier treated for a UL variant were obtained, and 
the diagnoses were reexamined by a pathologist (R.C.B.) 
via the corresponding hematoxylin-eosin slides. Two pul-
monary tumor samples with high cellularity were obtained 
from the removed tumors, whereas the sample for the pul-
monary tumor with bizarre nuclei was obtained via core-
needle biopsy. The study was approved by the appropriate 
ethics committee of the Hospital District of Helsinki and 
Uusimaa, Helsinki, Finland (88/13/03/03/2015), and the 
National Supervisory Authority for Welfare and Health 
(8522/06.01.03.01/2015), and it is in accordance with the 
Declaration of Helsinki.
The presence of UL driver mutations was previously 
analyzed for all conventional tumors and for a subset of 
variant tumors.6 Similar analyses were now performed 
for the remaining samples. In brief, MED12 exons 1 and 
2 were analyzed by direct sequencing, and HMGA2 and 
FH expression was analyzed by immunohistochemistry. 
For immunohistochemical analyses, tissue microarrays 
were constructed as previously described.6 HMGA2 
expression was analyzed with an anti-HMGA2 anti-
body (1:2000; 59170AP; Biocheck, Inc, Foster City, 
California), and FH inactivation was assessed with an 
anti-FH antibody (1:1000; clone J-13, sc-100743; Santa 
Cruz Biotechnology, Inc, Dallas, Texas). ATRX and 
DAXX immunolabeling was performed with anti-ATRX 
(1:500; HPA001906; Sigma-Aldrich, St. Louis, Missouri) 
and anti-DAXX antibodies (1:500; HPA008736; Sigma-
Aldrich) as previously described.8 Whole sections were 
analyzed from samples that showed aberrant expression 
or failed on tissue microarrays. All staining was analyzed 
and scored by a pathologist (R.C.B.) with a 3-grade scale: 
strong expression (++), normal/weak expression (+), or no 
expression (–). Retained staining in endothelial or in-
flammatory cells was used as an internal positive control.
Telomere-specific fluorescence in situ hybridiza-
tion was applied to determine the presence of ALT. A 
cyanine 3–labeled peptide nucleic acid probe (F1006-5; 
Panagene, Daejeon, South Korea) was used as previously 
described.8 The imaging and digitalization of tissue mi-
croarray sections were performed with a Pannoramic P250 
Flash II digital slide scanner (3DHISTECH, Budapest, 
Hungary) equipped with a Zeiss Plan-Apochromat 40×/
NA 0.95 objective and a pco.edge 4.2 complementary 
metal-oxide semiconductor camera (CMOS) along with 
the DAPI shift-free (E) filter set (DAPI-1160B-000) and 
the 43 HE Cy 3 shift-free (E) filter set (489043-9901-
000). Pannoramic Viewer (version 1.15.3; 3DHISTEC) 
was used to annotate samples. The whole tissue sec-
tions were imaged with a Zeiss Axio Imager.Z2 upright 
epifluorescence microscope (Carl Zeiss, Oberkochen, 
Germany) equipped with a Hamamatsu Orca Flash 4.0 
LT 4-megapixel monochrome scientific CMOS digital 
camera (Hamamatsu Photonics, Hamamatsu, Japan) and 
Zeiss Zen 2 Pro software. ALT was scored independently 
by 2 authors (T.V.A. and N.M.M./P.v.N.), and 300 cells 
were calculated from each sample. Samples displaying 
big, heterogeneous, and abnormally bright intranuclear 
DNA foci in ≥5% of the cells were considered positive. 
Whole sections were analyzed from samples considered 
positive or showing aberrant or unclear telomeres on tis-
sue microarrays.
RESULTS
Here we analyzed ATRX and DAXX expression 
and the presence of ALT in 142 variant ULs and 64 
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conventional ULs. Aberrations were detected in 9 vari-
ant ULs (9 of 142 [6.3%]; Table 1 and Fig. 1A): ATRX 
expression was lost in 6 tumors (6 of 142 [4.2%]), 1 
tumor showed DAXX loss (1 of 142 [0.7%]), and 4 
tumors displayed ALT (4 of 142 [2.8%]). The major-
ity of the tumors harbored only 1 aberration (7 of 9 
[77.8%]), whereas 2 tumors showed both ATRX loss 
and ALT. We also identified 2 ALT-positive tumors, 
which expressed normal levels of both ATRX and 
DAXX; this indicates that there are other mechanisms 
that underlie the alternating telomere length in these 
tumors. Aberrations were found in all histopathological 
UL variant subgroups studied. All conventional ULs 
had normal levels of ATRX and DAXX expression, and 
none displayed ALT.
The great majority of conventional ULs harbor 
mutations in MED12 or overexpress HMGA2.3 Tumors 
with either one of these driver mutations display rela-
tively few other mutations.12 Here, 53 of 64 conventional 
tumors (83%) displayed either a MED12 mutation or 
HMGA2 overexpression. In contrast, MED12 mutations 
or HMGA2 overexpression were identified in only 40 of 
142 variant ULs (28%). All tumors with ATRX/DAXX 
loss or ALT were wild-type for MED12 and HMGA2 
(Table 1).
We further examined the medical histories of 9 pa-
tients whose tumors displayed ATRX/DAXX loss and/
or ALT. Two patients were later diagnosed with pulmo-
nary smooth muscle tumors (Table 2 and Fig. 1B). One 
of these 2 patients had a pulmonary leiomyoma 12 years 
after hysterectomy. The uterine and pulmonary leiomy-
omas displayed highly similar histologies, including bi-
zarre nuclei. The uterine tumor was ALT-positive, and 
the pulmonary tumor showed both ATRX loss and ALT. 
The other patient was diagnosed with 2 pulmonary leio-
myosarcomas, the first 8 years and the second 11 years 
after hysterectomy. The uterine tumor showed highly cel-
lular histopathology, ATRX loss, and FH loss, whereas 
both pulmonary sarcomas displayed ATRX loss, ALT, 
and FH loss. These findings suggest dissemination of the 
uterine tumors to the lungs.
DISCUSSION
ATRX is a chromatin remodeling protein that interacts 
with DAXX and plays a role in telomere integrity.10 
Dysfunctional ATRX and DAXX have been associated 
with the ALT phenotype, and a strong correlation be-
tween the loss of ATRX or DAXX expression and ALT 
has been observed in several malignancies, including 
ULMS.8-11 Currently, the role of ATRX/DAXX in ALT 
is not well understood. ALT-positive ULMSs with no 
detectable loss of ATRX or DAXX have been reported, 
and this indicates that other mechanisms contribute to 
telomere length in these tumors.9 Here, 6.3% of UL 
variants (9 of 142) had a loss of ATRX or DAXX and/
or ALT, whereas all conventional ULs displayed normal 
expression and telomeres. These aberrations were found 
in variant tumors that were negative for MED12 and 
HMGA2 aberrations, and this further emphasizes the 
differences between the molecular characteristics and 
pathogenesis mechanisms of conventional and vari-
ant ULs. Two of the 9 samples displayed both a loss of 
ATRX expression and ALT, whereas 7 tumors displayed 
only 1 aberration, suggesting that other mechanisms 
regulate the manifestation of ALT hallmarks in these 
tumors.














Conventional 64 37 (58) 16 (25) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Histopathological subtypes 142 21 (15) 19 (13) 6 (4.2) 1 (0.7) 2 (1.4) 2 (1.4) 9 (6.3)
Highly cellular 45 1 (2.2) 7 (16) 1 (2.2) 0 (0) 0 (0) 0 (0) 1 (2.2)
Cellular 35 6 (17) 10 (29) 0 (0) 1 (2.9) 0 (0) 0 (0) 1 (2.9)
Bizarre nuclei 31 4 (13) 0 (0) 4 (13) 0 (0) 1 (3.2) 2 (6.5) 5 (16)
Mitotically active 16 7 (44) 2 (13) 1 (6.3) 0 (0) 0 (0) 0 (0) 1 (6.3)
(Highly) cellular and 
mitotically active
15 3 (20) 0 (0) 0 (0) 0 (0) 1 (6.7) 0 (0) 1 (6.7)
Abbreviations: ALT, alternative lengthening of telomeres; ATRX, alpha-thalassemia/mental retardation syndrome X-linked; DAXX, death domain–associated 
protein; HMGA2, high-mobility group AT-hook 2; MED12, mediator complex subunit 12.
Percentages are presented in parentheses.
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The leiomyoma subtype with the most frequent 
ATRX, DAXX, and/or ALT aberrations was UL with bi-
zarre nuclei because 5 of the 31 tumors (16%) displayed 
alterations. These tumors are characterized by irregularly 
shaped nuclei or several hyperchromatic nuclei and eo-
sinophilic cytoplasm.4 Accumulating evidence suggests 
that their genetic and clinical characteristics share traits 
with those of ULMS, and this in part separates this group 
from other ULs. The most common molecular defect in 
these tumors is biallelic FH inactivation, which has been 
identified in more than 30% of tumors and is much more 
common in this UL subtype than other ULs.6,13 MED12 
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mutations, in turn, are significantly less frequent in these 
tumors than in conventional ULs, and the mutation fre-
quency resembles that observed in ULMSs.5,8,14 Also, TP53 
mutations, which are some of the most common alterations 
in ULMSs,8,14,15 have been identified in ULs with bizarre 
nuclei.14 These tumors reoccur more often than other UL 
subtypes.14,16 Although ULMSs are considered to develop 
as de novo tumors, microscopically visible colocalization 
with ULs with bizarre nuclei has been reported together 
with shared genetic changes.17 These findings support the 
hypothesis that some ULs with bizarre nuclei may harbor 
malignant potential and progress into ULMSs.
Cellular and especially highly cellular ULs have 
substantially increased cellularity in comparison with 
nearby myometrium, and their features resemble, in 
part, those associated with endometrial stromal tu-
mors.4 Genetic findings indicate that the molecular 
pathogenesis of highly cellular ULs mostly differs from 
that of conventional ULs; these tumors harbor the least 
amount of known UL driver aberrations, with nearly 
80% of the tumors having no identified underlying mo-
lecular defect.6 Here, 1 highly cellular tumor showed 
a loss of ATRX expression (1 of 45 [2.2%]), and 1 cel-
lular tumor showed a loss of DAXX expression (1 of 
35 [2.9%]). Although cellular and highly cellular ULs 
share some features with ULMSs, the key molecular de-
fects leading to the development of these tumors remain 
to be determined.
Mitotically active ULs are defined as having more 
than 10 mitoses per 10 high-power fields.4 In contrast 
to cellular ULs and ULs with bizarre nuclei, mitotically 
active ULs have a relatively high MED12 mutation fre-
quency, and they have not been shown to harbor alter-
ations typically associated with malignant tumors.6,14 In 
this study, 1 mitotically active tumor showed a loss of 
ATRX expression (1 of 16 [6.3%]), and 1 tumor with 
both increased cellularity and mitotic activity displayed 
ALT (1 of 15 [6.7%]). Thus, some tumors of this UL sub-
type also have mutations associated with malignancy.
When the medical history was scrutinized for the 9 
patients whose tumors showed ATRX/DAXX loss and/
or ALT, 2 patients were found to have been diagnosed 
with pulmonary smooth muscle tumors years after UL 
removal. Pulmonary and uterine tumors displayed sim-
ilar molecular alterations, and this suggested possible 
extrauterine dissemination of ULs and thus a condition 
known as benign metastasizing leiomyoma (BML) in 
these patients. BML is a rare disease in which women 
with a previous history of UL develop smooth muscle tu-
mors outside the uterus. The lungs are the predominant 
site of metastasis, and the average time of the pulmonary 
tumor diagnosis is 8.8 years after UL removal.18 The 
clinical course of BML is typically indolent, although 
rare malignant transformation has been reported.19,20 
The exact mechanism of BML pathogenesis remains un-
resolved, but pulmonary metastasis via hematogenous 
circulation has been suggested. Identical genetic aber-
rations and elongated telomeres have been identified in 
UL–pulmonary tumor pairs, and this suggests the clonal 
origin of these tumors.21-23 One of the patients identified 
here had an FH-deficient UL, and the pulmonary tu-
mors also displayed FH loss. FH loss is a known but rare 
driver event in UL and leads to severe metabolic stress 
due to deficient tricarboxylic acid cycle function. One 
BML patient with a germline FH mutation has been re-
ported, but the FH status of the tumors is not known.24 
Further studies with additional samples are warranted to 
verify the possible contributions of ATRX, ALT, and/or 
FH to BML pathogenesis.
In conclusion, we here show that a subset of UL 
variants display ATRX or DAXX loss and/or ALT. These 
features have been associated with several malignancies, 
especially brain tumors and sarcomas.8-11 Aberrations 
were identified in each UL subtype but in none of the 
conventional tumors. Two patients with ATRX loss or 
ALT were later diagnosed with a pulmonary smooth 
muscle tumor, and this suggested extrauterine dissem-
ination. Together with the previous data, these results 
Figure 1. (A) Representative images of histopathology, ATRX/DAXX expression, and telomere lengths in uterine LMs: 
conventional LM with normal ATRX and DAXX expression and telomeres; LM BN with ATRX loss and normal DAXX expression 
and telomeres; mitotically active and cellular LM with normal ATRX and DAXX expression and ALT; LM BN with ATRX loss, normal 
DAXX expression, and ALT; and cellular LM with normal ATRX expression, DAXX loss, and normal telomeres. (B) ATRX/DAXX 
expression and telomere lengths in uterine LMs and pulmonary smooth muscle tumors from 2 patients. The uterine-pulmonary 
LM BN pair included a uterine tumor with normal ATRX, DAXX, and FH expression and ALT and a pulmonary tumor with a loss of 
ATRX, ALT, and normal expression of DAXX and FH. The highly cellular uterine LM–pulmonary LMS pairs included a uterine tumor 
with a loss of ATRX and FH expression and normal DAXX expression and telomeres and pulmonary LMS I and pulmonary LMS II 
(operated 8 and 11 years after hysterectomy, respectively) with a loss of ATRX and FH, normal DAXX expression, and ALT. ALT 
indicates alternative lengthening of telomeres; ATRX, alpha-thalassemia/mental retardation syndrome X-linked; DAXX, death 
domain–associated protein; FH, fumarate hydratase; HE, hematoxylin-eosin; LM, leiomyoma; LM BN, leiomyoma with bizarre 
nuclei; LMS, leiomyosarcoma. Scale bar 50 µm for HE and IHC images, and 10 µm for telomere-specific FISH images. [Colour 
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highlight the differences in the molecular pathogenesis 
of conventional ULs and UL variants. The findings also 
raise concern about the long-term malignant potential of 
some UL variants, which are currently treated and oper-
ated on as benign tumors. Additional data are required 
to determine the potential role of ATRX and/or ALT in 
malignant transformation and to evaluate their feasibil-
ity in diagnostics. The identification of tumors with ma-
lignant potential could affect treatment procedures and 
eventually prevent malignant transformation.
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